Portfolio company
Arpida AG
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biopharmaceutical company develops novel antibiotics for hospital patients to treat severe infections caused by drug-resistant bacteria.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Arpida
This company develops antimicrobial drugs and broad-spectrum antibiotics to treat patients with severe bacterial infections requiring hospital treatment.
Calixa Therapeutics
This biopharmaceutical company develops novel antibiotics to treat serious infections caused by multi-drug-resistant pathogens for hospital patients.
Omnix Medical
This biopharmaceutical company develops novel antibiotic agents for patients suffering from life-threatening, drug-resistant bacterial infections.
Nabriva
This biopharmaceutical company develops and commercialises novel antibiotics for patients with serious infections caused by drug-resistant bacteria.
Cerexa
This biopharmaceutical company develops hospital-based anti-infective therapies for patients with serious and life-threatening infections.
C10 PHARMA
This biopharmaceutical company develops novel antibiotics to treat life-threatening bacterial infections and combat antimicrobial resistance for patients with unmet medical needs.
Abgentis
This company develops broad-spectrum antibacterial drugs for pharmaceutical firms to treat acute, chronic, and drug-resistant infections.
Acurx Pharmaceuticals
This biopharmaceutical company develops small molecule antibiotics to treat patients with bacterial infections caused by priority pathogens.